Literature DB >> 12576327

Idiotype vaccination in multiple myeloma induced a reduction of circulating clonal tumor B cells.

Thomas Rasmussen1, Lotta Hansson, Anders Osterborg, Hans Erik Johnsen, Håkan Mellstedt.   

Abstract

Myeloma cells express the idiotype (Id)-specific antigen that may be targeted by Id vaccination. Six patients with stage I IgG myeloma were immunized with the autologous purified M component together with the adjuvant cytokines interleukin 12 (IL-12) alone or in combination with granulocyte-macrophage colony-stimulating factor (GM-CSF). The effect of Id vaccination on circulating clonal tumor B cells was monitored by a real-time allele-specific oligonucleotide polymerase chain reaction method. No other treatment was given. Reduction of blood tumor mass was observed in 4 of 6 patients, with one patient achieving a complete molecular remission in blood. In 3 of these 4 patients an Id-specific T-cell response was induced. In the remaining 2 patients with an unchanged level of blood tumor cells, one patient mounted a T-cell response, whereas the other did not. No significant change in the serum M protein level was noted. Id vaccination may target clonal B cells, suggesting that this strategy might be conducive to achieving tumor control. The clinical significance of these findings remains to be established.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 12576327     DOI: 10.1182/blood-2002-06-1925

Source DB:  PubMed          Journal:  Blood        ISSN: 0006-4971            Impact factor:   22.113


  15 in total

Review 1.  Immunotherapy strategies for multiple myeloma: the present and the future.

Authors:  Frederick L Locke; Taiga Nishihori; Melissa Alsina; Mohamed A Kharfan-Dabaja
Journal:  Immunotherapy       Date:  2013-09       Impact factor: 4.196

2.  Vaccination with dendritic cell/tumor fusion cells results in cellular and humoral antitumor immune responses in patients with multiple myeloma.

Authors:  Jacalyn Rosenblatt; Baldev Vasir; Lynne Uhl; Simona Blotta; Claire Macnamara; Poorvi Somaiya; Zekui Wu; Robin Joyce; James D Levine; Dilani Dombagoda; Yan Emily Yuan; Karen Francoeur; Donna Fitzgerald; Paul Richardson; Edie Weller; Kenneth Anderson; Donald Kufe; Nikhil Munshi; David Avigan
Journal:  Blood       Date:  2010-10-28       Impact factor: 22.113

Review 3.  Cancer stem cells in multiple myeloma.

Authors:  Nilanjan Ghosh; William Matsui
Journal:  Cancer Lett       Date:  2008-09-21       Impact factor: 8.679

4.  Identification of a new HLA-A2-restricted T-cell epitope within HM1.24 as immunotherapy target for multiple myeloma.

Authors:  Michael Hundemer; Stefanie Schmidt; Maud Condomines; Alaviana Lupu; Dirk Hose; Marion Moos; Friedrich Cremer; Christian Kleist; Peter Terness; Sebastian Belle; Anthony D Ho; Hartmut Goldschmidt; Bernard Klein; Olaf Christensen
Journal:  Exp Hematol       Date:  2006-04       Impact factor: 3.084

Review 5.  Peptide vaccines for hematological malignancies: a missed promise?

Authors:  Monica Bocchia; Marzia Defina; Lara Aprile; Anna Sicuranza
Journal:  Int J Hematol       Date:  2014-01-08       Impact factor: 2.490

Review 6.  Autologous stem cell transplantation and multiple myeloma cancer stem cells.

Authors:  William Matsui; Ivan Borrello; Constantine Mitsiades
Journal:  Biol Blood Marrow Transplant       Date:  2012-01       Impact factor: 5.742

Review 7.  Immune therapies.

Authors:  Rao H Prabhala; Nikhil C Munshi
Journal:  Hematol Oncol Clin North Am       Date:  2007-12       Impact factor: 3.722

Review 8.  Multiple myeloma cancer stem cells.

Authors:  Carol Ann Huff; William Matsui
Journal:  J Clin Oncol       Date:  2008-06-10       Impact factor: 44.544

9.  Identification of HLA-A2 restricted T-cell epitopes within the conserved region of the immunoglobulin G heavy-chain in patients with multiple myeloma.

Authors:  Sebastian Belle; Fang Han; Maud Condomines; Olaf Christensen; Mathias Witzens-Harig; Bernd Kasper; Christian Kleist; Peter Terness; Marion Moos; Friedrich Cremer; Dirk Hose; Anthony D Ho; Hartmut Goldschmidt; Bernard Klein; Michael Hundemer
Journal:  Eur J Haematol       Date:  2008-03-19       Impact factor: 2.997

Review 10.  Immunotherapy of cancer by IL-12-based cytokine combinations.

Authors:  Jonathan M Weiss; Jeff J Subleski; Jon M Wigginton; Robert H Wiltrout
Journal:  Expert Opin Biol Ther       Date:  2007-11       Impact factor: 4.388

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.